ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer

Table 1 Characteristics of the patients and ADAR1 expression in cancer cells

		ADAR1 (nucleus)			ADAR1 (cytoplasm)
		Low	High	P value	Low	High	P value
Age	≦68 (Median)	43	38	0.580	42	39	0.688
Age	> 68 (Median)	34	36		34	36
Gender	M	45	42	0.834	48	39	0.165
Gender	F	32	32		28	36
Stage IV or recurrent	Stage IV	49	53	0.295	48	54	0.246
Stage IV or recurrent	Recurrent	28	21		28	21
Location	Right	17	24	0.153	16	25	0.090
Location	Left	60	50		60	50
Colon or rectum	Colon	42	42	0.785	37	47	0.084
Colon or rectum	Rectum	35	32		39	28
CEA (ng/ml)	≦5.0	22	20	0.832	20	22	0.679
CEA (ng/ml)	> 5.0	55	54		56	53
CA19-9 (U/ml)	≦37	51	42	0.231	48	45	0.690
CA19-9 (U/ml)	> 37	26	32		28	30
Neoadjuvant chemotherapy	YES	49	43	0.486	52	40	0.057
Neoadjuvant chemotherapy	NO	28	31		24	35
Pathology	Differentiated	65	51	0.024	63	53	0.075
Pathology	Undifferentiated	12	23		13	22
Lymph node metastasis	Absent	30	8	0.000	28	10	0.001
Lymph node metastasis	Present	47	66		48	65
Number of lymph node metastases	≦4	58	38	0.002	55	41	0.024
Number of lymph node metastases	> 4	19	36		21	34
Liver metastasis	Absent	15	13	0.762	15	13	0.704
Liver metastasis	Present	62	61		61	62
Number of liver metastasis	≦3	57	42	0.026	54	45	0.153
Number of liver metastasis	> 3	20	32		22	30
Type of liver metastasis	Synchronous	38	46	0.232	39	45	0.547
Type of liver metastasis	Metachronous	24	15		22	17
RAS mutation	Mutant	26	27	0.726	25	28	0.568
RAS mutation	Wild	51	47		51	47

ISSN: 1476-4598